Moderna And GSK Hit By Declining RSV Vaccines Expectations

The efficacy of Moderna’s jab appears to fade faster than its rivals, while experts were surprised by an FDA panel’s recommendation to narrow the use of all three RSV vaccines.

Vaccine injection

More from Business

More from Scrip